Innocan Pharma (CSE: INNO- OTC: INNPF) CEO Iris Bincovich joined Steve Darling from Proactive with news the company has hit a major milestone in the development of CLX Therapy which holds the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells.
Bincovich telling Proactive they have been able to successfully complete a large-scale production of exosomes. The company is still in the development stage of the CLX platform but this step shows part of the path to commercialization.